Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07516509 · ClinicalTrials.gov registry record
Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations in Insulin Resistance
A clinical trial, sponsored by AdventHealth Translational Research Institute.
- Not yet
- Registry status
- 36
- Enrollment target
NCT07516509 is a clinical trial that has not yet begun recruiting, run by AdventHealth Translational Research Institute. The registered enrollment target is 36 participants.
The verdict
NCT07516509 has not yet begun recruiting, sponsored by AdventHealth Translational Research Institute.
- NOT YET RECRUITING
- Registry status
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to find new signs or signals in muscle cells that can help us understand when the body isn't responding well to insulin (a condition called insulin resistance).
Interventions
- OTHER DEXA
- OTHER VO2 Max
- OTHER Peripheral Microvascular Reactivity
- OTHER Skeletal Muscle Insulin Sensitivity
- OTHER Non-Oxidative Glucose Disposal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07516509
The ClinicalTrials.gov registry entry for NCT07516509 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which DEXA is the first listed.
NCT07516509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07516509 about?
NCT07516509 is a clinical study titled "Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations in Insulin Resistance". The purpose of this study is to find new signs or signals in muscle cells that can help us understand when the body isn't responding well to insulin (a condition called insulin resistance).
What is the current status of trial NCT07516509?
This trial is currently not yet recruiting. The enrollment target is 36 participants. The study started on 2026-06. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07516509?
The interventions under investigation include: DEXA (OTHER), VO2 Max (OTHER), Peripheral Microvascular Reactivity (OTHER), Skeletal Muscle Insulin Sensitivity (OTHER), Non-Oxidative Glucose Disposal (OTHER).
Who is sponsoring clinical trial NCT07516509?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.